Loading
A phase 2 trial in lung cancer, run by Maastricht University Medical Center, now recruiting.
Boosting Osimertinib Blood Brain Barrier Penetration is a phase 2, interventional study registered as NCT07485452 by Maastricht University Medical Center, with a registry enrolment figure of 7 participants, started 2026-06 and due to reach its primary completion in 2027-06. Interventions recorded: Osimertinib & febuxostat. Conditions listed: Non-Small Cell Lung Cancer. Primary outcome: Effect of combining osimertinib with febuxostat on osimertinib CSF:plasma ratio in patients with EGFR NSCLC without CNS metastases. Lung eligibility wording from the registry: "The patient has metastatic EGFR-mutated NSCLC and is treated with osimertinib as part of regular care with CT-confirmed stable disease or better". Sites: Netherlands. No results are recorded here; the registry entry is the source.
Shares Lung cancer trials open today (registry snapshot), AstraZeneca, Non-small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Non-small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Non-small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Non-small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Non-small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Non-small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Non-small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Non-small-cell lung cancer and the tag lung-deep-dive.